NewsNovo
Three healthcare stocks are outpacing the S&P 500 and the so-called Magnificent Seven in 2026, yet Wall Street analysts largely remain skeptical of their near-term valuation.
With less than two months left in the year, the broad market index is on pace for another double-digit gain, but only Nvidia and Apple among the Magnificent Seven are beating the market.
Investors seeking higher returns have turned to Moderna, Twist Bioscience, and 10X Genomics, which have delivered exceptional gains despite recent price pullbacks.
Moderna shares have surged more than 620% so far in 2026, marking a performance that exceeds the company's gains during the 2020 and 2021 pandemic peak.
Keep reading